The global Systemic Fluoroquinolones market size is predicted to grow from US$ 1029 million in 2025 to US$ 1362 million in 2031; it is expected to grow at a CAGR of 4.8% from 2025 to 2031.
Fluoroquinolones are a class of systemic broad-spectrum antimicrobial agents that are widely used to treat respiratory and urinary tract infections. The mechanism of action primarily involves the inhibition of bacterial DNA gyrase and topoisomerase IV, blocking DNA replication in bacteria, thereby exerting an antimicrobial effect. Fluoroquinolones are highly effective against a wide range of aerobic Gram-positive and Gram-negative bacteria, and are commonly used to treat respiratory and urinary tract infections caused by pathogens such as Streptococcus pneumoniae, Escherichia coli, and Klebsiella species. In addition, fluoroquinolones are also utilized for certain gastrointestinal infections, bone and joint infections, and soft tissue infections. Due to their favorable pharmacokinetic properties, fluoroquinolones are typically administered orally or intravenously, and they offer significant therapeutic benefits. However, it is important to note that prolonged or inappropriate use may lead to side effects, such as tendonitis and cardiovascular issues.
United States market for Systemic Fluoroquinolones is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Systemic Fluoroquinolones is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Systemic Fluoroquinolones is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Systemic Fluoroquinolones players cover Bayer, Fresenius, CJ CheilJedang, Eurofarma, Sanofi, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LPI (LP Information)' newest research report, the “Systemic Fluoroquinolones Industry Forecast” looks at past sales and reviews total world Systemic Fluoroquinolones sales in 2024, providing a comprehensive analysis by region and market sector of projected Systemic Fluoroquinolones sales for 2025 through 2031. With Systemic Fluoroquinolones sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Systemic Fluoroquinolones industry.
This Insight Report provides a comprehensive analysis of the global Systemic Fluoroquinolones landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Systemic Fluoroquinolones portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Systemic Fluoroquinolones market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Systemic Fluoroquinolones and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Systemic Fluoroquinolones.
This report presents a comprehensive overview, market shares, and growth opportunities of Systemic Fluoroquinolones market by product type, application, key players and key regions and countries.
Segmentation by Type:
Ciprofloxacin
Levofloxacin
Ofloxacin
Norfloxacin
Moxifloxacin
Others
Segmentation by Application:
Hospitals
Clinics
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Bayer
Fresenius
CJ CheilJedang
Eurofarma
Sanofi
Daiichi Sankyo
Sandoz
Teva Pharmaceutical
Sun Pharmaceutical
SPIMACO
Guangzhou Green Cross Pharmaceutical
Yangtze River Pharmaceutical
Southwest Pharmaceutical
Zhejiang Medicine
Shandong Qidu Pharmaceutical
Sichuan Kelun Pharmaceutical
Chongqing Yaoyou Pharmaceutical
Apeloa Pharmaceutical
Shandong Lukang Pharmaceutical
Nanjing Zenkom Pharmaceutical
United Laboratories
Gooddoctor Pharmaceutical
CSPC Pharmaceutical Group
Please note: The report will take approximately 2 business days to prepare and deliver.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook